Engineered iPSCs and persistent immune effector cells
Patent Information
- Application Number
- JP2023526068
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-04
- Filing Date
- 2021-11-04
- Publication Date
- 2024-11-13
Smart Images

Figure 00000104_0000 
Figure 00000104_0001 
Figure 00000104_0002
Abstract
Claims
1. 1. A cell or population thereof, wherein (a) the cell comprises a polynucleotide encoding a recombinant cytokine signaling complex and optionally a chimeric antigen receptor (CAR); (b) the cell is an induced pluripotent cell (iPSC), a eukaryotic cell, an animal cell, a human cell, an immune cell, a feeder cell, or a derivative cell differentiated from the iPSC; and (c) the cytokine signaling complex comprises (i) a complete or partial cytokine, and (ii) a complete or partial IL7 receptor, IL2 receptor, IL4 receptor, IL9 receptor, IL21 receptor, or γC receptor.
2. 2. The cell or population thereof of claim 1, wherein the cytokine signaling complex is co-expressed with the CAR in a separate construct or in a bicistronic construct.
3. The iPSCs are clonal iPSCs, single cell dissociated iPSCs, iPSC cell line cells, or iPSC Master Cell Bank (MCB) cells, or the derived cells are (i) derived CD34 + 2. The cell or population thereof of claim 1, comprising a derived hematopoietic stem progenitor cell, a derived hematopoietic multipotent progenitor cell, a derived T cell precursor, a derived NK cell precursor, a derived T lineage cell, a derived NKT lineage cell, a derived NK lineage cell, or a derived B lineage cell; or (ii) a derived effector cell having one or more functional attributes not present in a corresponding primary T, NK, NKT, and / or B cell.
4. The cytokine signaling complex comprises a partial or complete peptide of IL7 and an IL7 receptor, the cytokine signaling complex comprising: (a) (i) IL7 protein and IL7Rα (IL7RF) protein (ii) IL7 and IL7Rα co-expressed by using a self-cleaving peptide; (iii) an IL7 / IL7Rα fusion protein in which the intracellular domain of IL7Rα has been truncated or eliminated; (iv) a fusion protein of IL7 and IL7Rβ; (v) a fusion protein of IL7 and common receptor γC, wherein the common receptor γC is natural or modified; and (vi) a homodimer of IL7Rβ; Any one of (i)-(vi) is optionally co-expressed with the CAR, either in a separate construct or in a bicistronic construct; as needed, (b) A cell or a population thereof according to any one of claims 1 to 3, which is transiently expressed.
5. The cells, (i) CD38 knockout, (ii) HLA-I deficiency and / or HLA-II deficiency, (iii) introduction of HLA-G or non-cleavable HLA-G, or knockout of either or both of CD58 and CD54; (iv) exogenous CD16 or a variant thereof; (v) chimeric fusion receptors (CFRs); (vi) partial or complete peptides of cell surface expressed exogenous cytokines and / or their receptors; (vii) at least one of the genotypes listed in Table 1; (viii) a deletion or disruption of at least one of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, TCR, NKG2A, NKG2D, CD25, CD69, CD44, CD56, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, and TIGIT; or (ix) HLA-E, 4-1BBL, CD3, CD4, CD8, CD16, CD47, CD113, CD131, CD137, CD80, PDL1, A 2A5. The cell or population thereof of any one of claims 1 to 4, further comprising one or more of the following: an antigen-specific TCR, an Fc receptor, an antibody or a functional variant or fragment thereof, a checkpoint inhibitor, an engager, and introduction of at least one of a surface triggering receptor for coupling to an agonist.
6. the cells are compared to their corresponding primary cells obtained from peripheral blood, umbilical cord blood, or any other donor tissue that does not have the same gene edit; (i) increased cytotoxicity, (ii) improved persistence and / or survival; (iii) an enhanced ability to migrate and / or activate or recruit bystander immune cells to the tumor site; (iv) improved tumor penetration; (v) enhanced ability to reduce tumor immunosuppression; (vi) improved ability to rescue tumor antigen escape; (vii) regulated apoptosis; (viii) enhanced or gained ADCC, and (ix) the ability to avoid fratricide; The cell or population thereof of claim 4, having therapeutic properties including one or more of the following:
7. The exogenous CD16 or a variant thereof (a) high affinity non-cleavable CD16 (hnCD16); (b) F176V and S197P in the ectodomain of CD16; (c) a complete or partial ectodomain derived from CD64; (d) a non-native (or non-CD16) transmembrane domain; (e) a non-native (or non-CD16) intracellular domain; (f) a non-native (or non-CD16) signaling domain; (g) a non-naturally occurring stimulatory domain, and (h) the cell or population thereof described in claim 5, comprising at least one of transmembrane, signaling, and stimulatory domains not derived from CD16 and derived from the same or a different polypeptide.
8. The cells include derived effector cells differentiated from the iPSCs, and further the derived effector cell, compared to a corresponding cell that does not have the cytokine signaling complex, (a) improved relative cell proliferation; (b) the increased percentage of CAR expression; (c) increased CD69 expression, and (d) decreased PD-1 expression; The cell or population thereof according to claim 4, comprising at least one of the following:
9. The CAR is (i) T cell-specific or NK cell-specific; (ii) bispecific antigen binding CAR; (iii) a switchable CAR; (iv) a dimerized CAR, (v) split CAR, (vi) multi-chain CAR; (vii) an inducible CAR; (viii) inactivated CAR; (ix) optionally co-expressed with a checkpoint inhibitor, either in a separate construct or in a bicistronic construct; (x) specific for at least one of CD19, BCMA, CD20, CD22, CD38, CD123, HER2, CD52, EGFR, GD2, MICA / B, MSLN, VEGF-R2, PSMA, and PDL1; and / or (xi) ADGRE2, carbonic anhydrase IX (CAIX), CCR1, CCR4, carcinoembryonic antigen (CEA), CD3, CD5, CD7, CD8, CD10, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CDS, CLEC12A, antigen of cytomegalovirus (CMV)-infected cells, epithelial glycoprotein -2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), EGFRvIII, receptor tyrosine protein kinase erb-B2, 3, 4, EGFIR, EGFR-VIII, ERBB folate binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), human epidermal growth factor receptor 2 (HER2), human telomerase reverse transcriptase Enzyme (hTERT), ICAM-1, integrin B7, interleukin-13 receptor subunit alpha-2 (IL-13Rα2), kappa-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9), Lewis Y (LeY), L1 cell adhesion molecule (L1-CAM), LILRB2, melanoma antigen family A1 (MAGE-A1), MICA / B, mucin 1 (Muc-1), mucin 16 (Muc-16), mesothelin (MSLN), NKC specific for any one of SI, NKG2D ligand, c-Met, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), PRAME, prostate stem cell antigen (PSCA), PRAME prostate specific membrane antigen (PSMA), tumor associated glycoprotein 72 (TAG-72), TIM-3, TRBC1, TRBC2, vascular endothelial growth factor R2 (VEGF-R2), Wilms tumor protein (WT-1), and pathogen antigens, and optionally The cell or population thereof according to any one of claims 1 to 4, wherein the CAR of any one of (i) to (xi) is inserted into a TCR locus and / or is driven by an endogenous promoter of the TCR, and / or the TCR is knocked out by the CAR insertion.
10. The cell or population thereof of claim 9, wherein the inactivated CAR targets a surface protein that is upregulated in activated recipient immune cells.
11. The cell or population thereof according to claim 10, wherein the inactivated CAR comprises at least one of CD38-CAR, 4-1BB-CAR, OX40-CAR, and CD40L-CAR.
12. The cell or population thereof of claim 5, wherein the CFR comprises an ectodomain fused to a transmembrane domain, the transmembrane domain being operably connected to an endodomain, and the ectodomain, the transmembrane domain, and the endodomain do not comprise any endoplasmic reticulum (ER) retention or endocytosis signals.
13. 13. The cell or population thereof of claim 12, wherein the ectodomain of the CFR comprises a full length or partial length of the extracellular portion of a signaling protein comprising at least one of CD3ε, CD3γ, CD3δ, CD28, CD5, CD16, CD64, CD32, CD33, CD89, NKG2C, NKG2D, any functional variant thereof, and combinations or chimeras thereof.
14. The ectodomain of the CFR initiates signaling upon binding to a selected agonist that includes at least a binding domain specific for the extracellular portion of CD3, CD28, CD5, CD16, CD64, CD32, CD33, CD89, NKG2C, NKG2D, or any functional variant thereof, or the selected agonist ... 44, CD79a, CD79b, CD123, CD138, CD179b, CEA, CLEC12A, CS-1, DLL3, EGFR, EGFRvIII, EPCAM, FLT-3, FOLR1, FOLR3, GD2, gpA33, HER2, HM1.24, LGR5, MSLN, MCSP, MICA / B, PSMA, PAMA, P-cadherin, or ROR1.
15. wherein the endodomain of the CFR comprises a cytotoxic domain comprising at least the entire length or a portion of a CD3ζ, 2B4, DAP10, DAP12, DNAM1, CD137 (4-1BB), IL21, IL7, IL12, IL15, NKp30, NKp44, NKp46, NKG2C, or NKG2D polypeptide, and optionally wherein the endodomain comprises (i) a costimulatory domain comprising a full length or portion of a CD2, CD27, CD28, CD40L, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D polypeptide, or any combination thereof; (ii) a costimulatory domain comprising the full length or a portion of CD28, 4-1BB, CD27, CD40L, ICOS, CD2, or a combination thereof; (iii) a tonic signaling domain comprising the full length or a portion of the internal domain of a cytokine receptor, including IL7R, IL15R, IL18R, IL12R, IL23R, or a combination thereof; and / or (iv) the cell or population thereof described in any one of claims 12 to 14, further comprising one or more of a receptor tyrosine kinase (RTK), a tumor necrosis factor receptor (TNFR), an EGFR, or a complete or partial intracellular portion of a FAS receptor.
16. The checkpoint inhibitor is selected from the group consisting of PD-1, PDL-1, TIM-3, TIGIT, LAG-3, CTLA-4, 2B4, 4-1BB, 4-1BBL, A 2A 6. The cell or population thereof of claim 5, which is an antagonist to one or more checkpoint molecules including R, BATE, BTLA, CD39, CD47, CD73, CD94, CD96, CD160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxp1, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2, Rara (retinoic acid receptor alpha), TLR3, VISTA, NKG2A / HLA-E, and inhibitory KIR.
17. The cells, (i) one or more exogenous polynucleotides integrated into a safe harbor locus or a selected locus; or (ii) three or more exogenous polynucleotides integrated into different safe harbor loci or two or more selected loci.
18. 18. The cell or population thereof of claim 17, wherein the safe harbor locus comprises at least one of AAVS1, CCR5, ROSA26, collagen, HTRP, H11, GAPDH, or RUNX1, or the selected locus is one of B2M, TAP1, TAP2, tapasin, NLRC5, CIITA, RFXANK, RFX5, RFXAP, TCR, NKG2A, NKG2D, CD38, CD25, CD44, CD58, CD54, CD56, CD69, CD71, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, or TIGIT, and / or the integration of the exogenous polynucleotide knocks out expression of a gene at the locus.
19. The cell or population thereof described in claim 18, wherein the TCR locus is the constant region of TCR alpha and / or TCR beta.
20. The cell or population thereof according to claim 3 or 4, wherein the derived effector cells are of the T lineage and are expanded in a culture medium that does not contain exogenous IL15.
21. The cell or population thereof of claim 20, wherein the culture medium comprises one or both of exogenous IL2 and IL7.
22. The cell or population thereof of claim 20 , wherein the culture medium does not contain either IL2 or IL7.
23. The derived effector cells are + and / or PD1 - Or PD1 低 The cell or population thereof according to any one of claims 20 to 22,
24. 23. The cell or population thereof of any one of claims 20 to 22, wherein the derived effector cell has increased anti-tumor function and / or persistence compared to its corresponding cell not having the cytokine signaling complex in the absence of cytokine support.
25. 1. A method for improving T lineage cell proliferation and / or tumor cell control and clearance, comprising introducing an IL7 cytokine signaling complex into said T lineage cells, thereby producing T lineage cells having improved cell proliferation and / or tumor cell control and clearance compared to corresponding cells not having said cytokine signaling complex, said T lineage cells optionally further comprising a chimeric antigen receptor (CAR).
26. 26. The method of Claim 25, wherein the introducing step comprises: (i) engineering induced pluripotent cells (iPSCs) to produce genome-edited iPSCs that comprise a polynucleotide encoding the IL7 cytokine signaling complex and optionally a CAR; and (ii) differentiating the genome-edited iPSCs into derived T lineage cells that comprise the IL7 signaling complex.
27. The genome-edited iPSCs are compared to their corresponding primary cells obtained from peripheral blood, umbilical cord blood, or any other donor tissue that do not have the same gene edit; (i) CD38 knockout, (ii) HLA-I deficiency and / or HLA-II deficiency, (iii) introduction of HLA-G or non-cleavable HLA-G, or knockout of either or both of CD58 and CD54; (iv) exogenous CD16 or a variant thereof; (v) chimeric fusion receptors (CFRs); (vi) partial or complete peptides of cell surface expressed exogenous cytokines and / or their receptors; (vii) at least one of the genotypes listed in Table 1; (viii) a deletion or disruption of at least one of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, TCR, NKG2A, NKG2D, CD25, CD69, CD44, CD56, CIS, CBL-B, SOCS2, PD1, CTLA4, LAG3, TIM3, and TIGIT; or (ix) HLA-E, 4-1BBL, CD3, CD4, CD8, CD16, CD47, CD113, CD131, CD137, CD80, PDL1, A 2A R, introduction of at least one of an antigen-specific TCR, an Fc receptor, an antibody or a functional variant or fragment thereof, a checkpoint inhibitor, an engager, and a surface triggering receptor; 27. The method of claim 26, further comprising one or more edits resulting in:
28. 27. The method of claim 26, further comprising expanding said T lineage cells containing said IL7 cytokine signaling complex in culture medium that does not contain exogenous IL15.
29. 29. The method of claim 28, wherein the culture medium comprises one or both of exogenous IL2 and IL7.
30. 29. The method of claim 28, wherein the culture medium does not contain either IL2 or IL7.
31. The T lineage cells are + and / or PD1 - Or PD1 低 The method according to any one of claims 28 to 30, wherein
32. The method according to any one of claims 25 to 30, wherein said improved cell proliferation and / or tumor cell control and clearance is in vitro and / or in vivo.
33. A method for improving the in vivo anti-tumor function of CAR-T cells according to the method of any one of claims 25 to 30.
34. A composition comprising a cell or a population thereof according to any one of claims 1 to 24.
35. A Master Cell Bank (MCB) comprising a clonal iPSC according to any one of claims 1 to 24.
36. A composition for therapeutic use comprising derived effector cells differentiated from the iPSCs of any one of claims 1 to 24 and one or more therapeutic agents.
37. 37. The composition of claim 36, wherein the one or more therapeutic agents comprise a peptide, a cytokine, a checkpoint inhibitor, an antibody or a functional variant or fragment thereof, a mitogen, a growth factor, a small RNA, a dsRNA (double stranded RNA), a mononuclear blood cell, a feeder cell, a feeder cell component or a replenisher thereof, a vector comprising one or more polynucleic acids of interest, a chemotherapeutic agent or a radioactive moiety, or an immunomodulatory drug (IMiD).
38. (a) the checkpoint inhibitor is (i) PD-1, PDL-1, TIM-3, TIGIT, LAG-3, CTLA-4, 2B4, 4-1BB, 4-1BBL, A 2A one or more antagonist checkpoint molecules, including R, BATE, BTLA, CD39, CD47, CD73, CD94, CD96, CD160, CD200, CD200R, CD274, CEACAM1, CSF-1R, Foxpl, GARP, HVEM, IDO, EDO, TDO, LAIR-1, MICA / B, NR4A2, MAFB, OCT-2, Rara (retinoic acid receptor alpha), TLR3, VISTA, NKG2A / HLA-E, or inhibitory KIR; (ii) one or more of atezolizumab, avelumab, durvalumab, ipilimumab, IPH4102, IPH43, IPH33, lilimumab, monalizumab, nivolumab, pembrolizumab, and derivatives or functional equivalents thereof; or (iii) at least one of atezolizumab, nivolumab, and pembrolizumab; or (b) the composition of claim 37, wherein the therapeutic agent comprises one or more of venetoclax, azacitidine, and pomalidomide.
39. The antibody or functional variant or fragment thereof, (a) anti-CD20, anti-CD22, anti-HER2, anti-CD52, anti-EGFR, anti-CD123, anti-GD2, anti-PDL1, and / or anti-CD38 antibody, (b) one or more of rituximab, veltuzumab, ofatumumab, ublituximab, ocaratuzumab, obinutuzumab, ibritumomab, ocrelizumab, inotuzumab, moxetumomab, epratuzumab, trastuzumab, pertuzumab, alemtuzumab, cetuximab, dinutuximab, avelumab, daratumumab, isatuximab, MOR202, 7G3, CSL362, elotuzumab, and humanized or Fc-modified variants or fragments thereof, and functional equivalents and biosimilars thereof; or (c) the composition of claim 37, comprising daratumumab, and the derived effector cells comprising a CD38 knockout, and optionally expression of CD16 or a variant thereof.
40. 38. The composition of claim 37, wherein the cytokine is IL2.
41. Use of a composition described in any one of claims 34, or 36-40, in the manufacture of a medicament for treating an autoimmune disorder, a hematological malignancy, a solid tumor, cancer, or a viral infection.
42. 42. The use of claim 41, wherein the subject does not require cytokine support during therapeutic treatment.
43. 1. A method of producing a derived effector cell comprising a cytokine signaling complex and optionally a CAR, the method comprising: (i) differentiating engineered iPSCs into the derived effector cell, the iPSCs comprising a polynucleotide encoding the cytokine signaling complex and optionally the CAR; and (ii) expanding the derived effector cell in a culture medium that does not contain exogenous IL15, wherein the derived effector cell exhibits a higher proliferation rate than cells cultured in culture medium containing exogenous IL15. (a) increased cytotoxicity, (b) improved persistence and / or survival; (c) an enhanced ability to migrate and / or activate or recruit bystander immune cells to the tumor site; (d) improved tumor penetration; (e) enhanced ability to reduce tumor immunosuppression; (f) improved ability to rescue tumor antigen escape; (g) regulated apoptosis; (h) enhanced or gained ADCC; and (i) the ability to avoid fratricide; and growing the cells having therapeutic properties including one or more of the following:
44. 44. The method of claim 43, wherein the cytokine signaling complex comprises an IL7 receptor fusion (IL7RF).
45. 1. A method of producing a clonal master engineered iPSC line using CRISPR-mediated editing of a clonal iPSC, wherein the editing comprises knocking-in a polynucleotide encoding a cytokine signaling complex, and optionally a CAR, into the clonal iPSC, wherein the cytokine signaling complex comprises an IL7 receptor fusion (IL7RF), thereby producing the clonal master engineered iPSC line.
46. Use of a composition described in any one of claims 36 to 40 to treat a disease or condition in a subject in need of treatment.
